Showing 2041-2050 of 5839 results for "".
- Study: Individuals With Acne Face Social and Professional Stigmahttps://practicaldermatology.com/news/study-individuals-with-acne-face-social-and-professional-stigma/2462175/Individuals with acne face social and professional stigma, and people with darker skin tones and more severe acne are disproportionately more likely to face greater stigma. These results, published in JAMA Dermatology, highlight the need to identify ways to
- Is Separating the Good Skin T Cells from the Bad Ones a Key to Treating Psoriasis and Vitiligo?https://practicaldermatology.com/news/is-separating-the-good-skin-t-cells-from-the-bad-ones-a-key-to-treating-psoriasis-and-vitiligo/2462162/New research highlights ways to remove immune cells that cause autoimmune skin diseases such as psoriasis and vitiligo without affecting protective cells that fight infection and cancer. Tissue-resident T cells or TRM cells fight infections and cancerous cells in the skin, but
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid
- AD Pipeline Watch: Escient Pharmaceuticals Initiates Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonisthttps://practicaldermatology.com/news/ad-pipeline-watch-escient-pharmaceuticals-initiates-proof-of-concept-study-of-ep262-a-first-in-class-oral-mrgprx2-antagonist/2462155/The first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of Escient Pharmaceuticals’ EP262 in atopic dermatitis (AD). By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell medi
- FDA Grants Priority Review for Abeona's Pz-cel BLAhttps://practicaldermatology.com/news/fda-grants-priority-review-for-abeonas-pz-cel-bla/2462154/The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) of Abeona Therapeutics Inc.’s pz-cel (prademagene zamikeracel), an investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of patient
- Beyond the Headlines: Dr. Jonathan Silverberg Reviews Maintenance Data on Rademikibart From a Pivotal Trial in Chinahttps://practicaldermatology.com/news/beyond-the-headlines-dr-jonathan-silverberg-reviews-maintenance-data-on-rademikibart-from-a-pivotal-trial-in-china/2462152/DermWire recently reported positive topline results from a 52-week maintenance study of rademikibart in people with atopic dermatitis (AD). At
- First Patients Enrolled in Phase 2 Proof of Concept Trial of MC2-25 VLS in Vulvar Lichen Sclerosushttps://practicaldermatology.com/news/first-patients-enrolled-in-phase-2-proof-of-concept-trial-of-mc2-25-vls-in-vulvar-lichen-sclerosus/2462151/The first patients have been enrolled in a Phase 2a proof of concept trial evaluating the safety and efficacy of MC2-25 VLS, a new drug candidate for the treatment of urea- associated skin diseases, including vulvar lichen sclerosus. MC2-25 VLS is a based on a di-peptide that
- Scientists 3D-print Hair Follicles in Lab-grown Skinhttps://practicaldermatology.com/news/scientists-3d-print-hair-follicles-in-lab-grown-skin/2462137/Scientists at Rensselaer Polytechnic Institute have 3D-printed hair follicles in human skin tissue cultured in the lab. This marks the first time that researchers have used the technology to generate hair follicles. The findings appear in
- FDA Accepts sBLA for Interchangeability Designation for Hadlima, a Humira Biosimilarhttps://practicaldermatology.com/news/fda-accepts-sbla-for-interchangeability-designation-for-hadlima-a-biosimilar-to-humira/2462131/The U.S. Food and Drug Administration (FDA) has accepted the Supplemental Biologics License Application (sBLA) for the interchangeability designation or Hadlima (adalimumab-bwwd) injection 40 mg/0.4 mL, a biosimilar to Humira(adalimumab). Once a biosimilar product is designated as an in
- ACR: TREMFYA Improves Pain, Physical Function and Fatigue in PsA Patients Through Six Monthshttps://practicaldermatology.com/news/acr-tremfya-improves-pain-physical-function-and-fatigue-in-psa-patients-through-six-months/2462121/Substantial numbers of people living with treatment-resistant active PsA who used TREMFYA (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months, according to new data from the CorEvitas Psoriatic Arthritis (PsA) and Spo